Multi-omics identifies circulating mirna and protein biomarkers for facioscapulohumeral dystrophy

Cooperative International Neuromuscular Research Group (CINRG) Investigators

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The development of therapeutics for muscle diseases such as facioscapulohumeral dystrophy (FSHD) is impeded by a lack of objective, minimally invasive biomarkers. Here we identify circulating miRNAs and proteins that are dysregulated in early-onset FSHD patients to develop blood-based molecular biomarkers. Plasma samples from clinically characterized individuals with early-onset FSHD provide a discovery group and are compared to healthy control volunteers. Low-density quantitative polymerase chain reaction (PCR)-based arrays identify 19 candidate miRNAs, while mass spectrometry proteomic analysis identifies 13 candidate proteins. Bioinformatic analysis of chromatin immunoprecipitation (ChIP)-seq data shows that the FSHD-dysregulated DUX4 transcription factor binds to regulatory regions of several candidate miRNAs. This panel of miRNAs also shows ChIP signatures consistent with regulation by additional transcription factors which are up-regulated in FSHD (FOS, EGR1, MYC, and YY1). Validation studies in a separate group of patients with FSHD show consistent up-regulation of miR-100, miR-103, miR-146b, miR-29b, miR-34a, miR-454, miR-505, and miR-576. An increase in the expression of S100A8 protein, an inflammatory regulatory factor and subunit of calprotectin, is validated by Enzyme-Linked Immunosorbent Assay (ELISA). Bioinformatic analyses of proteomics and miRNA data further support a model of calprotectin and toll-like receptor 4 (TLR4) pathway dysregulation in FSHD. Moving forward, this panel of miRNAs, along with S100A8 and calprotectin, merit further investigation as monitoring and pharmacodynamic biomarkers for FSHD.

Original languageEnglish (US)
Article number236
Pages (from-to)1-22
Number of pages22
JournalJournal of Personalized Medicine
Volume10
Issue number4
DOIs
StatePublished - Nov 2020

Bibliographical note

Funding Information:
Funding: This study is supported by funding from the Friends of FSH Research, the FSHD Society, Muscular Dystrophy Canada, and the FSHD Global Research Foundation. C.R.H. and this work is supported by the National Institutes of Health (NIH) grants R01HL153054, P50HD090254, and R00HL130035, as well as the Foundation to Eradicate Duchenne and the A. James & Alice B. Clark Foundation. Y.W.C. is partially supported by NIH/NINDS 1R03NS116444, Muscular Dystrophy Association and NIH/NCATS UL1TR001876.

Funding Information:
This study is supported by funding from the Friends of FSH Research, the FSHD Society, Muscular Dystrophy Canada, and the FSHD Global Research Foundation. C.R.H. and this work is supported by the National Institutes of Health (NIH) grants R01HL153054, P50HD090254, and R00HL130035, as well as the Foundation to Eradicate Duchenne and the A. James & Alice B. Clark Foundation. Y.W.C. is partially supported by NIH/NINDS 1R03NS116444, Muscular Dystrophy Association and NIH/NCATS UL1TR001876.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Biomarkers
  • Calprotectin
  • Dystrophy
  • FSHD
  • MiRNA
  • Muscle
  • Proteomics

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Multi-omics identifies circulating mirna and protein biomarkers for facioscapulohumeral dystrophy'. Together they form a unique fingerprint.

Cite this